Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/IRCT20160530028182N7
IRCT20160530028182N7RecruitingPhase 2

Comparison Methylphenidate and Buspirone as Adjuant therapy in children with ADHD treated by Methylphenidate mono therapy

Sanandaj University of Medical Sciences0 sites50 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 2
Status
Recruiting
Sponsor
Enrollment
50
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
6 years to 12 years (—)
Sex
All

Inclusion Criteria

  • •Age between 6 -12 years
  • •Diagnosis of ADHD and ODD based on DSM5
  • •without effective medication taking on mental status at least 2 weeks before the study

Exclusion Criteria

  • •Intelectual disability based on clinical suspicious
  • •presence of uncontroled siezure
  • •Drug side effects and hypersensivity
  • •Recieving of any other drugs
  • •History of psychological disorder except for ADHD and ODD
  • •presence of medical deasese such as cardiac deaseses

Investigators

Sponsor
Sanandaj University of Medical Sciences

Similar Trials

Completed
Phase 2
Buspirone in ADHDAttention Deficit Hyperactivity Disorder.Disturbance of activity and attention
IRCT138901292000N3Behavioral Sciences and Research Center of Shahid Beheshti University of Medical Sciences.34
Recruiting
Phase 3
Comparison of opioid maintenance treatments (OMTs) in priso
IRCT20170702034844N7Faran Shimi Pharmaceutical Company100
Completed
Not Applicable
Buspirone in ADHDAttention Deficit Hyperactivity Disorder.Disturbance of activity and attention
IRCT201104116168N1euroscience Research Center Kerman University of Medical Sciences, Kerman ,Iran40
Completed
Not Applicable
the effect of buprenorphine and methadone in the reduction of methamphetamine cravingMethamphetamine Dependency.Mental and behavioural disorders due to use of other stimulants, including caffeine
IRCT2015112125160N1Shiraz University of Medical Sciences40
Not yet recruiting
Not Applicable
COMPARISON OF BUTORPHANOL VERSUS MORPHINE AS AN ADDITION TO EPIDURAL ROPIVACAINE FOR POSTOPERATIVE PAIN RELIEF IN UTERUS RELATED SURGERIES
CTRI/2021/12/038609SUDHAS
Effect of Buspirone in ADHD | Clinical Trial